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Strengths and limitations of this study
 ► This systematic review will update and extend the 
evidence regarding the effects of minocycline in 
psychiatric and neurological disorders; this is the 
first review to present these two fields together.
 ► Data will be extracted by two independent reviewers.
 ► Rigorous screening processes and assessment of 
included studies will allow only for peer- reviewed 
publications.
 ► A potential limitation of this systematic review may 
be the lack of studies in some of the conditions, 
making it unfeasible to perform a meta- analysis.
AbStrACt
Introduction Due to the anti- inflammatory, antioxidant 
and anti- apoptotic properties of minocycline, clinical trials 
have evaluated the potential of this drug to treat several 
psychiatric and neurological disorders, including major 
depressive disorder, schizophrenia, bipolar disorder, stroke 
and amyotrophic lateral sclerosis. This protocol proposes 
a systematic review (and potential meta- analysis) that 
aims to identify and critically evaluate randomised 
controlled trials of minocycline for treating psychiatric and 
neurological disorders.
Methods and analysis PubMed, Embase, Cochrane 
Central Register of Controlled Clinical Trials, PsycINFO 
and Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) will be used to identify randomised 
controlled trials that used minocycline to treat psychiatric 
and neurological disorders. Double- blind, randomised, 
controlled, clinical trials of participants aged 18 years or 
older and written in English will be included in the review. 
Data will be extracted by two independent reviewers. 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses guidelines will be followed and the 
Cochrane Collaboration’s ‘Risk of Bias’ tool will be used 
to assess the risk of bias in all studies included in the 
systematic review. The Grading of Recommendations, 
Assessment, Development and Evaluation system will be 
used to access the overall quality of the level of evidence 
of the studies. If sufficient evidence is identified, a 
meta- analysis will be conducted using the standardised 
mean difference approach and reported with 95% CIs. 
Heterogeneity of evidence will be evaluated using the I2 
model.
Ethics and dissemination This systematic review will 
evaluate only published data; therefore, ethical approval is 
not required. The systematic review will be published in a 
peer- reviewed journal and presented at relevant research 
conferences.
trial registration number CRD42020153292.
IntroduCtIon
Minocycline (7‐dimethylamino‐6‐demethyl‐6‐
deoxytetracycline) is a second‐generation 
semi‐synthetic tetracycline antibiotic. It is used 
to treat several bacterial infections as well as 
severe acne and rheumatoid arthritis.1 Minocy-
cline is a highly lipophilic drug and can cross 
the blood–brain barrier.2 It is well tolerated in 
humans with either acute or chronic use.3
Minocycline has been proposed as a novel 
intervention for psychiatric and neurological 
disorders due to its anti- inflammatory, antiox-
idant and anti- apoptotic properties, in addi-
tion to its ability to promote neurogenesis.4–6 
Several neuropsychiatric and neurologic 
disorders have been associated with neuroin-
flammation.7–12 Minocycline is known to 
have inhibitory effects on microglial acti-
vation.4 This inhibition aids to attenuate 
neuroinflammation and may be beneficial 
in preventing cognitive and behavioural 
impairments. In addition, the antioxidant 
properties of minocycline, including free‐
radical scavenging activity and inhibition of 
lipid peroxidation, have been described in 
several studies.13 14 Minocycline also presents 
cytoprotective properties by reducing apop-
tosis. This can be explained at least in part 
by its effect on the expression of the anti‐
apoptotic B- cell lymphoma protein-2 (Bcl‐2) 
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and antagonising pro- apoptotic proteins such as Bax, 
Bak and Bid.15 16 This, in turn, suppresses the activation 
of caspases 1 and 3 and the release of apoptotic factors 
such as cytochrome c from mitochondria, reducing cell 
death.15 16 Minocycline additionally enhances neurogen-
esis in several preclinical models.17 18
These aforementioned properties led to several studies 
designed to evaluate the potential of minocycline to treat 
several psychiatric and neurological disorders, including 
major depressive disorder (MDD), schizophrenia, bipolar 
disorder, stroke and amyotrophic lateral sclerosis (ALS). 
Regarding the current use of minocycline in psychiatry, 
there have been recent systematic reviews from Zheng 
et al19 reporting that adjunctive minocycline treatment 
improved total symptoms in schizophrenia patients, but 
failed to demonstrate primary efficacy for bipolar depres-
sion and MDD. With respect to MDD, the findings of 
Zheng et al are in contrast to the work of Rosenblat and 
McIntyre which showed a positive effect of minocycline on 
depressive symptoms.20 This can be explained by the fact 
that Zheng et al only included studies with minocycline 
as monotherapy and Rosenblat and McIntyre included 
studies where minocycline was an adjunctive treatment. 
Similarly, secondary outcomes were not explored by 
Zheng and colleagues. On the other hand Xiang et al21 
and Solmi et al22 also demonstrated a potential positive 
effect of minocycline in schizophrenia.
In neurology, Malhotra et al23 reviewed the effects of 
minocycline in acute ischaemic stroke (AIS) and acute 
intracerebral haemorrhage showing efficacy especially in 
the AIS group. The potential of minocycline in Parkin-
son’s disease, Huntington’s disease and ALS has been 
previously discussed in the literature; however to the 
best of our knowledge, no systematic review has been 
conducted to evaluate the effects of minocycline in these 
conditions.
In animal models, some deleterious effects of minocy-
cline have been reported in the literature. Diguet et al 
suggest that minocycline may have deleterious effects 
in Parkinson’s models according to the mode of admin-
istration and dose.24 Vogt et al showed no antidepres-
sant effects at doses from 20 to 40 mg/kg in a C57BL/6 
mouse.25 Minocycline ameliorated brain injury in devel-
oping rats, but worsened the injury in the developing 
C57BL/6 mouse.26 Pro- apoptotic properties of mino-
cycline were demonstrated in developing mouse brain, 
raising concerns of its use in children.27
There is clear justification to explore the potential use 
of minocycline across psychiatric and neurological disor-
ders that share dysregulation in inflammation, oxidative 
pathways, apoptosis and neurogenesis. There are signif-
icant overlaps in pathophysiology between many psychi-
atric and neurological conditions. Minocycline potentially 
addresses these common factors, such as inflammation 
and oxidative stress.
Since the publication of earlier reviews6 28 more data 
are available that may enhance the understanding of 
the clinical utility of minocycline across neuropsychiatry. 
More studies allow for exploration of secondary outcomes 
and subgroups, especially in disorders with high clinical 
heterogeneity such as depression. As mentioned earlier, 
there is no systematic evaluation of the use of minocy-
cline in neurology; thus given its use in this field, bringing 
together the current evidence would be both timely 
and valuable. Therefore, there is value in exploring the 
evidence regarding the use of minocycline across fields to 
better understand its potential clinical usefulness.
objECtIvES
This systematic review aims to identify and critically eval-
uate randomised controlled trials of minocycline for 
treating psychiatric and neurological disorders. A compre-
hensive understanding of the current level of evidence in 
the literature will help clarify the clinical utility of minocy-
cline in each disease and inform future research.
MEthodS And AnAlySIS
This systematic review will be conducted in accordance 
with the Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses (PRISMA) guidelines.29 The 
Preferred Reporting Items for Systematic review and 
Meta- Analysis Protocols (PRISMA- P) checklist is attached 
as online supplementary file 1. It will include randomised 
controlled trials of minocycline of any size and dura-
tion in adult populations (≥18 years). The design of the 
studies can be placebo or active- controlled, parallel group 
or cluster design. Studies which have included more than 
one pharmacological intervention will also be included, 
with the data being pooled when possible. Only studies 
published in English will be included. Additional infor-
mation will be requested from the study authors if insuf-
ficient details are provided in the manuscript. All studies 
conducted to the present will be included.
The primary outcome of this systematic review will 
be improvement in core psychiatric or neurological 
symptoms after treatment with minocycline. Secondary 
outcomes include assessing the effects of minocycline 
treatment on quality of life, functioning, cognition, 
anxiety, disability, survival time and time to relapse. 
Adverse drug reactions and discontinuation rates will also 
be evaluated.
Search strategy
The PICO (Patient/Problem/Population, Intervention, 
Comparison/Control, Outcome) framework was used 
to develop the search strategy for this review. PubMed, 
Embase via  embase. com, Cochrane Central Register 
of Controlled Clinical Trials via  cochranelibrary. com, 
PsycINFO via EBSCO and CINAHL Complete via EBSCO 
will be used to search for the relevant literature up to 
March 2020. The appropriate index terms for each data-
base will be used. The online supplementary file 2 shows 
the full search strategy for PubMed and will be adapted 
to fit with other databases. The references cited in the 
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included publications will be searched for additional 
studies. Studies published since journal inception to the 
date the searches are run will be included. The searches 
will be re- run prior to the final analyses and any further 
studies identified will be retrieved for inclusion.
The studies extracted from the search will be checked 
for eligibility based on a selection of criteria. First, the 
titles and abstracts will be assessed to determine if the 
study is a randomised controlled trial, investigating an 
intervention with minocycline and has been conducted 
on participants with a psychiatric or neurologic disease. 
Subsequently, the full- text papers will be reviewed. A 
second reviewer will evaluate all articles at each stage of 
screening. If there is disagreement regarding eligibility, a 
third independent reviewer will determine the conclusive 
decision.
data management
An online reference management database, Covidence,30 
will be used to manage the data. Covidence allows 
abstracts and full text screening, handling of duplicate 
data, assessment of the risk of bias and extraction of the 
study outcomes based on inclusion and exclusion criteria.
Data will be extracted by two reviewers and it will 
include: (a) study identification details, (b) study design, 
(c) population characteristics, (d) intervention details, 
(e) outcome measurements, (f) information for assess-
ment of the risk of bias. Authors will be contacted where 
substantial outcomes of interest are not reported and/or 
clarification about study design is required.
Assessment of methodological quality
The Cochrane Collaboration’s ‘Risk of Bias’ tool will be 
used to assess the risk of bias in all studies included in 
this review.31 This tool covers six domains of bias: selec-
tion bias, performance bias, detection bias, attrition bias, 
reporting bias, and other bias and scores the randomised 
trials as low, high or unknown risk of bias. The overall 
quality of the level of evidence of the studies will be 
measured with the Grading of Recommendations, Assess-
ment, Development and Evaluation system.32
data synthesis and statistical analysis
A narrative synthesis of the findings will be reported, 
including population characteristics, type of outcome 
and intervention details.
If sufficient data are available, a meta- analysis will be 
performed for each diagnostic category.30–33 For contin-
uous data, mean differences or standardised mean differ-
ences with 95% CIs will be calculated. Dichotomous data 
will be analysed using risk ratios with 95% CIs. Mean 
differences will be used when the treatment outcome has 
been measured by the same scale. Standardised mean 
differences will be used when the treatment outcome has 
been measured by different scales in different studies. 
Sample size, SD and p values will be reported. Signifi-
cance will be set at α≤0.05.
To assess the statistical heterogeneity of evidence, I2 
will be used in accordance with the suggestions from the 
Cochrane Handbook for Systematic Reviews of Interven-
tions 5.1.34 Studies will be scored as low (I2 value of 25%), 
moderate (I2 value of 50%) or high (I2 value of 75%).
Sensitivity analysis will be performed to evaluate the 
robustness of the meta- analysis outcome.
Subgroup analysis
The following subgroup analyses will be performed if 
sufficient data are available:
 ► Trial treatment duration.
 ► Effect of treatment at different doses.
 ► Patient demographics (age, gender and illness 
severity).
 ► Biomarkers of inflammation and oxidative stress.
Presentation and reporting of results
This review will follow the PRISMA- P guidelines35 for 
reporting data. A PRISMA- P flow chart will describe study 
selection and numbers excluded at each stage of the 
process (and the appropriate reasons for exclusion).
Ethics and dissemination
Ethical approval is not required since this review will only 
include published data which already received ethical 
approval prior to publication. This review has been 
registered on PROSPERO. The results of this systematic 
review will be published in a peer- reviewed journal and 
presented at relevant scientific conferences.
no patient and public involvement
This research was done without patient involvement. 
Patients were not invited to comment on the study 
design and were not consulted to develop patient rele-
vant outcomes or interpret the results. Patients were not 
invited to contribute to the writing or editing of this docu-
ment for readability or accuracy.
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